Buprenorphine: extended‐release formulations “a game changer”!

2021 ◽  
Author(s):  
Katerina Lagios
Keyword(s):  
Extended Release ◽  
Extended Release Formulations ◽  
Game Changer

Formulation and In vitro Release Characterization of Metoprolol Succinate Extended Release Tablets

2012 ◽  
Vol 4 (4) ◽  
pp. 1537-1543
Author(s):  
Sakthikumar T ◽  
Rajendran N N ◽  
Natarajan R
Keyword(s):  
Drug Release ◽  
Extended Release ◽  
In Vitro Release ◽  
Methyl Cellulose ◽  
Wet Granulation ◽  
Direct Compression ◽  
Metoprolol Succinate ◽  
Extended Release Formulations ◽  
Vitro Release

The present study was aimed to develop an extended release tablet of metoprolol Succinate for the treatment of hypertension.  Four extended release formulations F1-F4 were developed using varying proportions of hydroxylpropyl-methylcellulose K100M, sodium carboxy methyl cellulose and Eudragit L30 D55 by wet granulation. Five extended release formulations F5-F9 containing HPMC K100M and HPMC 5 cps in varying concentration were developed by direct compression. The physicochemical and in vitro release characteristics of all the formulations were investigated and compared. Two formulations, F7 and F8 have shown not more 25% drug release  in 1st h, 20%-40% drug release at 4th hour, 40%-60% drug release at 8th hour and not less than 80% at 20th hour and the release pattern conform with USP specification for 24 hours extended release formulation. It can be conclusively stated that optimum concentration of HPMC K100M (58%-65%) by direct compression method can yield an extended release of metoprolol succinate for 24 hours.

Antibacterial glass-ionomer cement restorative materials: A critical review on the current status of extended release formulations

2017 ◽  
Vol 262 ◽  
pp. 317-328 ◽  
Author(s):  
Tahereh Mohammadi Hafshejani ◽  
Ali Zamanian ◽  
Jayarama Reddy Venugopal ◽  
Zahra Rezvani ◽  
Farshid Sefat ◽  
...  
Keyword(s):  
Critical Review ◽  
Extended Release ◽  
Glass Ionomer Cement ◽  
Current Status ◽  
Glass Ionomer ◽  
Restorative Materials ◽  
Extended Release Formulations ◽  
Ionomer Cement

Oral Extended-Release Formulations

2008 ◽  
pp. 1191-1222 ◽  
Author(s):  
Anette Larsson ◽  
Susanna Abrahmsn-Alami ◽  
Anne Juppo
Keyword(s):  
Extended Release ◽  
Extended Release Formulations

scholarly journals A Clinician's Guide to Oral Extended-Release Drug Delivery Systems in Epilepsy

2018 ◽  
Vol 23 (4) ◽  
pp. 277-292 ◽  
Author(s):  
James W. Wheless ◽  
Stephanie J. Phelps
Keyword(s):  
Adverse Effects ◽  
Extended Release ◽  
Extended Period ◽  
Immediate Release ◽  
Serum Drug Concentration ◽  
Neurologic Disorders ◽  
Dosing Regimens ◽  
Care Costs ◽  
Extended Release Formulations

Epilepsy is one of the most common chronic neurologic disorders that affects individuals of all ages. It is primarily managed with antiepileptic drugs (AEDs), with the goal of maintaining complete seizure control combined with minimal or no adverse effects. Oral administration is the mainstay of AED delivery for patients with chronic epilepsy and consists essentially of immediate-release (IR) and modified-release (delayed-release and extended-release [ER]) dosage formulations. Extended-release formulations (hydrophilic or hydrophobic matrix systems, reservoir systems, and osmotic-release systems) release a drug in a controlled manner during an extended period of time following administration. Extended-release formulations have many advantages compared with IR formulations, including simplification of dosing regimens, reduction in pill burden, and reduction in the peak-to-trough fluctuations in serum drug concentration that may be associated with a decreased risk of adverse effects and of seizures. These advantages have the potential to increase adherence to antiepileptic therapy, improve the quality of life of patients, and reduce health care costs. This article, which is intended as a practical guide for clinicians, reviews the properties of the different ER AED formulations currently available and discusses the advantages of ER over IR formulations. Subsequently, an explanation of the technologic basis of the different oral ER formulations, the critical attributes that differentiate ER products, and their individual strengths and weaknesses is provided. Specific recommendations to practitioners on treating patients with ER formulations are included.

Extended-Release Formulations in Epilepsy

2007 ◽  
Vol 22 (4) ◽  
pp. 419-426 ◽  
Author(s):  
Alberto Verrotti ◽  
Carmela Salladini ◽  
Giovanna Di Marco ◽  
Floriana Pisciella ◽  
Francesco Chiarelli
Keyword(s):  
Extended Release ◽  
Extended Release Formulations
Sign in / Sign up

Export Citation Format

Share Document